<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456688</url>
  </required_header>
  <id_info>
    <org_study_id>ARXB00434L</org_study_id>
    <nct_id>NCT02456688</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Imrecoxib in Subjects With Hepatic Insufficiency</brief_title>
  <official_title>An Open-label, Single-dose Study to Assess the Pharmacokinetics of Imrecoxib in Subjects With Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical research study will assess pharmacokinetics and the safety of Imrecoxib in
      patients with impaired hepatic function as compared to healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration time curve from 0 to infinity (AUC0-∞) after a single</measure>
    <time_frame>First 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma drug concentration (Cmax) after a single oral dose of</measure>
    <time_frame>First 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed plasma drug concentration (Tmax) after a single oral dose of Imrecoxib.</measure>
    <time_frame>First 5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (t½) after a single oral dose of Imrecoxib.</measure>
    <time_frame>First 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F) after a single oral dose of Imrecoxib.</measure>
    <time_frame>First 5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Patients with im paired hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imrecoxib</intervention_name>
    <arm_group_label>Patients with im paired hepatic function</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects:

          -  Between the ages of 18 to 70 years, with BMI 18~ 29kg/m2.

          -  In good health as determined by past medical history, physical examination, vital
             signs, electrocardiogram, and laboratory test values(except for values related to
             hepatic insufficiency).

        Hepatic impaired subjects:

          -  Hepatocirrhosis subjects verified by B-mode ultrasonography,CT ,MRI or Biopsy.

          -  A Child-Pugh Classification score clinically determined as Class B.

        Exclusion Criteria:

        All subjects:

          -  History of hypersensitivity to Imrecoxib or its components.

        Subjects diagnosed with tumor.

          -  History of or current clinically important systemic illnesses, including but not
             limited to cardiovascular, pulmonary, renal, hematological, gastrointestinal,
             endocrinological, immunological, dermatological, or psychiatric diseases.

          -  Have used any drugs or substances (including herbal supplements) known to inhibit or
             induce cytochrome P450 enzymes including cytochrome P450 3A4, cytochrome P450 2C8 and
             cytochrome P450 2C9 within 28 days prior to the first dose and throughout the study.

          -  Have taken other investigational drugs or participated in any clinical trial within 90
             days prior to first dose of study drug in this study.

        Hepatic impaired subjects:

          -  Subjects with hepatic failure,or severe complications caused by Hepatocirrhosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The frist affiliated hospital of Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>aidong Wen, Ph.D</last_name>
      <phone>029-84773636</phone>
      <email>adwen@fmmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>aidong Wen, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>xinmin Zhou, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

